[{"orgOrder":0,"company":"CBC Group","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"CBC Group","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"CBC Group","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.68000000000000005,"dosageForm":"Oral Syrup","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CBC Group","amount2":0.32000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.32000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"Adcentrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"CBC Group","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"2","companyTruncated":"CBC Group \/ CBC Group"}]

Find Clinical Drug Pipeline Developments & Deals by CBC Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : UCB is divesting its mature neurology and allergy business in China, which includes Keppra (levetiracetam), a medication used for the treatment of seizures, to CBC Group.

                          Product Name : Keppra

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 26, 2024

                          Lead Product(s) : Levetiracetam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : UCB Pharma S.A

                          Deal Size : $680.0 million

                          Deal Type : Divestment

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The funding was triggered by the first commercial sale of OLINVYK (oliceridine), contains oliceridine, an opioid, which is a Schedule II controlled substance, indicated in adults for the management of acute pain severe, in China by Jiangsu Nhwa.

                          Product Name : Olinvyk

                          Product Type : Other Small Molecule

                          Upfront Cash : $15.0 million

                          June 09, 2023

                          Lead Product(s) : Oliceridine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Trevena

                          Deal Size : $40.0 million

                          Deal Type : Financing

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, ...

                          Product Name : Edarbi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 20, 2023

                          Lead Product(s) : Azilsartan

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Hasten Biopharmaceutic

                          Deal Size : $315.0 million

                          Deal Type : Financing

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Series A financing is raised to power the development of next generation ADC for improving patient treatment options.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 28, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Adcentrx Therapeutics

                          Deal Size : $50.0 million

                          Deal Type : Series A Financing

                          blank